Scarica l'app Stockscreener
1.79
3.47%
0.06
Pre-mercato:
1.80
0.01
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.73
Aprire:
$1.75
Volume 24 ore:
209.92K
Relative Volume:
1.44
Capitalizzazione di mercato:
$30.16M
Reddito:
-
Utile/perdita netta:
$-52.53M
Rapporto P/E:
-0.4891
EPS:
-3.66
Flusso di cassa netto:
$-39.93M
1 W Prestazione:
+4.68%
1M Prestazione:
+86.50%
6M Prestazione:
+23.45%
1 anno Prestazione:
+7.19%
Intervallo 1D:
$1.725
$1.84
Intervallo di 1 settimana:
$1.56
$1.84
Portata 52W:
$0.9397
$2.02
Unity Biotechnology Inc Stock (UBX) Company Profile
Nome
Unity Biotechnology Inc
Settore
Industria
Telefono
(650) 416-1192
Indirizzo
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Confronta UBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
1.79 | 30.16M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-16 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-01-04 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-06-28 | Aggiornamento | Citigroup | Sell → Buy |
| 2021-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-16 | Downgrade | Citigroup | Neutral → Sell |
| 2020-08-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-18 | Downgrade | Mizuho | Buy → Neutral |
| 2020-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Iniziato | ROTH Capital | Buy |
| 2019-12-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Iniziato | Mizuho | Buy |
| 2018-05-29 | Iniziato | Citigroup | Buy |
| 2018-05-29 | Iniziato | Goldman | Neutral |
| 2018-05-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Unity Biotechnology Inc Borsa (UBX) Ultime notizie
Research Analysts Offer Predictions for UBX FY2024 Earnings - Defense World
Geode Capital Management LLC Buys 14,199 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Unity Biotechnology (NASDAQ:UBX) Coverage Initiated at Chardan Capital - Defense World
Chardan initiates Unity Biotechnology stock with Buy rating, cites senolytic UBX1325 potential - Investing.com India
Chardan Capital Initiates Coverage of Unity Biotechnology (UBX) with Buy Recommendation - MSN
UBXUnity Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Unity Biotechnology (NASDAQ:UBX) Shares Down 26.5% – Here’s What Happened - Defense World
UNITY Biotechnology Reports Granting of New Employment Inducement Award - GlobeNewswire
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
UNITY Biotech appoints new chief medical officer - Investing.com
UNITY Biotech Appoints SYFOVRE Developer Dr. Grossi as CMO Ahead of Key DME Trial Results - StockTitan
Unity Biotechnology, Inc. (NASDAQ:UBX): Is Breakeven Near? - Simply Wall St
We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate - Yahoo Finance
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com India
Unity Biotechnology stock hits 52-week low at $0.95 By Investing.com - Investing.com Nigeria
Unity Biotechnology stock hits 52-week low at $0.95 - Investing.com
Unity Biotechnology (NASDAQ:UBX) Trading Down 5.6% – What’s Next? - Defense World
Unity Biotechnology stock hits 52-week low at $1.1 - Investing.com
Unity Biotechnology stock hits 52-week low at $1.1 By Investing.com - Investing.com UK
Unity Biotechnology stock hits 52-week low at $1.1 amid challenges - Investing.com Canada
Unity Biotechnology (FRA:9U90) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com
Unity Biotechnology (STU:9U90) EV-to-Revenue : (As of Nov. 28, 2024) - GuruFocus.com
Finance Watch: Adcendo Pursues Proof-Of-Concept With $135m Series B Round - Citeline
Unity Biotechnology (FRA:9U90) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors - BioSpace
Alyeska Investment Group L.P.'s Strategic Acquisition in Unity B - GuruFocus.com
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Unity Biotechnology's CFO sells shares worth $175 - Investing.com India
Unity Biotechnology's chief legal officer sells shares worth $192 - Investing.com India
Unity Biotechnology's CFO sells shares worth $175 By Investing.com - Investing.com Canada
Unity Biotechnology's chief legal officer sells shares worth $192 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $1.15 - Investing.com
Unity Biotechnology CEO Anirvan Ghosh sells $557 in stock - Investing.com
Unity Biotechnology stock hits 52-week low at $1.15 By Investing.com - Investing.com Canada
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth? - Simply Wall St
Unity Biotechnology Focuses on Promising DME Treatment - TipRanks
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance UK
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Unity Biotechnology Inc Azioni (UBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):